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Objectives: To investigate whether blood–brain barrier (BBB) permeability is disrupted in normal appearing
white matter in MS patients, when compared to healthy controls and whether it is correlated with MS clinical
characteristics.
Methods: Dynamic contrast-enhanced MRI was used to measure BBB permeability in 27 patients with MS and
compared to 24 matched healthy controls.
Results: Permeability measured as Ktrans was signiﬁcantly higher in periventricular normal appearing white mat-
ter (NAWM) and thalamic gray matter in MS patients when compared to healthy controls, with periventricular
NAWM showing the most pronounced difference. Recent relapse coincided with signiﬁcantly higher permeabil-
ity in periventricular NAWM, thalamic gray matter, and MS lesions. Immunomodulatory treatment and recent
relapse were signiﬁcant predictors of permeability inMS lesions and periventricular NAWM. Our results suggest
that after an MS relapse permeability gradually decreases, possibly an effect of immunomodulatory treatment.
Conclusions:Our results emphasize the importance of BBB pathology inMS, which we ﬁnd to bemost prominent
in the periventricular NAWM, an area prone to development of MS lesions. Both the facts that recent relapse
appears to cause widespread BBB disruption and that immunomodulatory treatment seems to attenuate this
effect indicate that BBB permeability is intricately linked to the presence of MS relapse activity. This may reveal
further insights into the pathophysiology of MS.© 2013 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Multiple sclerosis (MS) is primarily an immune-mediated disease of
the central nervous system inwhich auto-aggressive T-cells are thought
to cross the blood–brain barrier (BBB) inﬂicting demyelination and ax-
onal loss eventually leading to progressive disability. A key event in MS
is the formation of acute gadolinium-enhancing lesions, resulting from
an overt breach of the BBB (Runge et al., 1985). In spite of intensive re-
search, the etiology of MS is largely unknown, but recent developments
in MS drug therapies have emphasized leukocyte passage across the
BBB as being of paramount importance for disease pathophysiology.
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lished by Elsevier Inc. All rights reserinactive MS lesions as well as normal appearing white matter
(NAWM) (Kirk et al., 2003; McQuaid et al., 2009; Plumb et al., 2002;
Vos et al., 2005), and serial MRI studies have indicated that structural
changes (Filippi et al., 1998; Werring, 2000) and BBB dysfunction
(Goodkin et al., 1998) may precedemyelin damage and leukocyte inﬁl-
tration. On the other hand, activated leukocytes themselves are capable
of altering BBB permeability through expression and secretion of in-
ﬂammatory cytokines (Larochelle et al., 2011). Hence, the sequence of
events is not entirely clear. Recent efforts have been made to use MRI
to compare permeability of the BBB in the NAWMofMS patients to cor-
responding white matter in healthy controls using changes in T1 after
gadolinium administration, but so far, studies have been inconclusive
(Lund et al., 2013; Silver et al., 2001). Ingrisch and colleagues successful-
ly used dynamic contrast enhanced (DCE) MRI, a method which is po-
tentially more sensitive when attempting to measure subtle changes
in BBB permeability, and reported a Ktrans of 0.04 mL/100 g/min in MS
NAWM, but included no healthy controls for comparison (Ingrisch
et al., 2012). Hence, the primary aim of this study was to use quantita-
tive dynamic contrast enhanced (DCE) MRI to investigate whether per-
meability of the BBB is increased in MS normal appearing brain tissue
compared to healthy tissue in controls. In MS patients we also wanted
to investigate any correlations between permeability in MS lesions
and normal appearing tissue and clinical characteristics, such asved.
183S.P. Cramer et al. / NeuroImage: Clinical 4 (2014) 182–189treatment status, disability, recent relapse activity and presence of
contrast-enhancing lesions.
2. Materials and methods
2.1. MS patients and healthy volunteers
We enrolled 27 RRMS patients (Table 1) from the MS clinic at
Glostrup Hospital, all referred to MRI as part of an evaluation prior to
initiation of second-line MS treatment, e.g. natalizumab or ﬁngolimod,
due to a high degree of disease activity and/or side-effects on current
or previous treatment. 18 patients were undergoing immunomodulato-
ry treatment at time of investigation (Table 1). Patient clinical data was
obtained fromhospital clinical records and included expandeddisability
status scale (EDSS), MS disease duration, current treatment status, and
history of clinical relapses 12 months prior to investigation. This proce-
durewas performed blinded to the permeability values. Relapsewasde-
ﬁned as new or worsening symptoms that lasted 24 h and occurred in
the absence of fever or infection (Schumacher et al., 1965). An experi-
enced physician, blinded to the permeability values, performed the pro-
cedure of going through the clinical records. Patients were excluded
from this study if they had been treated with corticosteroids within
the last 30 days. We included 24 matched healthy controls, who did
not have any ﬁrst-degree relatives withMS, and have any inﬂammatory
diseases or frequent migraine attacks (N1/month). MS patients and
healthy controlswere scanned in an interleaved fashion in order tomin-
imize the impact of slight scanner hardware differences (i.e. scanner
drift) over time on the results.
2.2. Ethics
This study was approved by the Ethics Committee of Copenhagen
County according to the standards of the National Committee on Health
Research Ethics, protocol number H-D-2008-002. All experiments were
conducted in accordance with the Helsinki Declaration of 1975 and all
subjects gave written informed consent.
2.3. Dynamic contrast enhanced (DCE) MRI
MRI was performed on a 3T MR unit (Philips Achieva) using a 32-
element phased-array head coil. DCE imaging used a T1-weightedTable 1
Demographics and permeability of the blood–brain barrier.
RRMS patients
(n = 27)
Healthy controls
(n = 24)
p-Value for
differencea
Age (years) 37.9 (10) 37.1 (12)
Gender (number of women) 19 16
EDSS score 2.8 (1.5) n/a
Disease duration (years) 6.1 (4.9) n/a
Treatment
None 9(b) 24
β-Interferon 15 n/a
Glatiramer acetate 3 n/a
Periventricular NAWM
Ktrans (mL/100 g/min) 0.09 (0.04) 0.04 (0.02) 0.9 × 10−5
No. of voxels 178 (98) 163 (68) 0.52
Thalamic gray matter
Ktrans (mL/100 g/min) 0.08 (0.03) 0.06 (0.03) 0.003
No. of voxels 91 (60) 86 (57) 0.37
NAGM
Ktrans (mL/100 g/min) 0.07 (0.04) 0.05 (0.04) 0.07
No. of voxels 59 (48) 61 (31) 0.88
Values are stated as mean (SD). Abbreviations: EDSS = expanded disability status scale.
NAWM = normal appearing white matter (cerebral white matter for healthy controls).
NAGM = normal appearing gray matter. RRMS = relapsing remitting MS.
a For statistical comparisons of Ktrans a one-tailed T testwas used. For comparisons of no.
of voxels a two-tailed T test was used.
b All patients but one were previously treated with β-interferon or glatiramer acetate.saturation-recovery gradient-echo sequence with ﬂip angle 30°,
TR = 3.9 ms, TE = 1.9 ms, centric phase ordering, parallel imaging fac-
tor 2, acquired matrix 96 × 61, ﬁeld-of-view 230 × 182 mm2, 5 slices,
slice thickness 8 mm. Data for an initial measurement of relaxation
time (T1) and equilibrium magnetization (M0) was generated using a
series of saturation time delays (TDs) from 120 ms to 10 s, covering
the same slices as imaged during the bolus passage. The dynamic se-
quence used a saturation time delay (TD) of 120 ms, giving a time res-
olution of 1.25 s, and 750 time points, corresponding to a total
sampling duration of 15.7 min. The automatic bolus injection (Spectris,
Medrad; USA) with speed 3–5 mL/s followed by 20 mL saline was
started after the 10th time point. Injection duration was approximately
1 s. The dose of contrast agent (Gadovist) was 0.045 mmol/kg
bodyweight. We acquired a separate slice at the level of the internal ca-
rotid artery (ICA) to obtain an arterial input function with minimal par-
tial volume. The remaining four DCE slices were used for deﬁning
regions of interest and subsequent tissue perfusion estimation. In
order to evaluate the scanner drift on our system over time we per-
formed a series of sham perfusion measurements (same DCE sequence
without contrast agent) and found a linear signal increase over
15 min in the order of 1–3%.
2.4. MRI sequences and regions of interest
Weused an axial T2-weightedMRI sequence (5 slices, TE = 100 ms,
TR = 3000 ms, ﬁeld-of-view = 230 × 119 mm2) with same orienta-
tion and slice thickness (8 mm) as our DCE sequence, in order to man-
ually draw regions of interest (ROIs) in the periventricular NAWM, the
normal appearing gray matter (NAGM) and in thalamic gray matter in
both hemispheres (Fig. 1).Wemanually deﬁned periventricular normal
appearing white matter by visual inspection performed by an experi-
enced MS investigator, and we took care not to include any visible T2-
lesions or areas visibly presenting themselves as diffusely abnormal
on a T2 image. For this procedure we used an axial T2 FLAIR sequence
(35 slices, TE = 125 ms, TR = 11,000 ms, ﬁeld-of-view = 230 ×
119 mm2, slice thickness of 3.5 mm) to check that no lesions were
present in the ROIs. For the healthy controls, we strived tomatch the an-
atomical location and size of the ROIs as close as possible (see Table 1).
Periventricular NAWM was placed at a minimum of 10 mm from any
MS lesions. In MS patients with visible contrast-enhancing lesions we
took care not to include the nearest 30 mm of non-enhancing tissue
into the periventricular NAWM. Due to lack of the appropriate MRI
sequence, we were not able to absolutely exclude gray matter lesions
from our NAGM ROIs. MS lesions were deﬁned as a T2 hyperintense
lesion, N3 mm in size with a typical anatomical location for MS, i.e.
periventricular, juxtacortical or infratentorial. An experiencedMS inves-
tigator performed this procedure manually. The distinction between
non-enhancing lesions (NELs) and contrast-enhancing lesions (CELs)
was made by visual inspection using a post gadolinium T1-weight se-
quence. Our four perfusion slices were placed in order to include the
largest number of MS lesions possible. Out of these lesions, we only in-
cluded those large enough to ﬁll the 8 mmDCE slices for further analy-
sis, in order to minimize partial volume effects. Out of a grand total of
498 visibly non-enhancing lesions identiﬁed on T2 and T2 FLAIR images
we were able to estimate permeability in 274 visibly non-enhancing le-
sions (mean number of lesions per patient 12.4; SD 8.9). All MS patients
had non-enhancing lesions, and ﬁve patients showed one or more con-
trast enhancing lesions on a post contrast T1 weighted image.
2.5. Permeability estimation
The DCE MRI data was analyzed with a semi-automatic procedure
(Larsson et al., 2008) using in-house MatLab-based software. The DCE
time series was converted to units of contrast agent concentration
using T1 and M0, as determined from the multiple saturation delay
data, and a contrast agent relaxivity of 4 s−1 mM−1. The input function
Fig. 1. A) On a T2-weighted anatomical MRI sequence, with same geometry as the four
acquired DCE perfusion slices, we placed regions of interest in periventricular normal
appearingwhitematter (green), normal appearing graymatter (blue), thalamic graymat-
ter (white), non-enhancing MS lesions (red) and contrast-enhancing MS lesions (white).
B) Map of voxel-wise calculation of Ktrans values for one MS patient. Marked with a red
arrow is a visibly enhancing MS lesion. Note also that the scalp is showing relatively
high values of permeability, due to the presence of extracranial vessels not expressing a
blood–brain barrier.
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ing thebolus passage and corrected for partial volumebynormalizing to
a phase derived venous outﬂow function, free of any partial volume ef-
fects (van Osch et al., 2001), sampled in the sagittal sinus (Hansen et al.,
2009). For each ROI the median value of permeability was extracted to
exclude effects of possible outliers. Every subject was represented by
one value calculated as a mean of the tissue speciﬁc ROIs (Fig. 1). Tissue
concentration–time curves were evaluated using a combination of
model free deconvolution and a Patlak model, as described in previous
work (Larsson et al., 2009). Example tissue enhancement curves andPatlak plots from one MS patient and one healthy control can be seen
in Fig. 2. Permeability values, Ktrans were calculated from Ki (full
blood) using the formula Ki = Ktrans / (1 − Hct). A ﬁxed value of
Hct = 0.45was used throughout the study. Values of Ktrans are reported
as mL/100 g/min assuming brain tissue density of 1 g/mL.
2.6. Statistics
Histograms, probability plots and modiﬁed Kolmogorov–Smirnov
(Lilliefors) testing were used to analyze for standard normal distribu-
tion ﬁt. Since we hypothesized that permeability would be higher in
MS patients, we used a one-tailed T test for statistical comparisons
between patients and healthy controls, and a p-value lower than 0.05
to allow us to reject the null hypothesis. For comparisons between sub-
groups of patients we used two-tailed T tests.We used a standard linear
regression approach to analyze for correlations with subject demo-
graphics and MS clinical parameters.
3. Results
In periventricular NAWM we found signiﬁcantly higher values of
BBB permeability inMS patients in comparison to cerebralwhitematter
of healthy controls (p = 0.9 × 10−5; one-tailed T test) (Fig. 3). In tha-
lamic gray matter we also found signiﬁcantly higher values in MS pa-
tients when compared to healthy controls (p = 0.003; one-tailed T
test). In NAGM no signiﬁcant difference was found (Table 1).
3.1. Clinical relapses and treatment status
In MS patients with one or more clinical relapses within the last
three months (n = 10) we found signiﬁcantly higher permeability
in periventricular NAWM (p = 0.004), thalamic gray matter (p =
0.004), and non-enhancing lesions (NELs) (p = 0.003; two-tailed T
tests), compared to patients with no relapses within the last three
months (n = 17) (Fig. 4). A linear regression analysis, modeling the
combined effect of treatment and recent relapse, showed that treatment
(Beta = −0.021 mL/100 g/min, p = 0.039) and relapsewithin the last
three months (Beta = 0.034 mL/100 g/min, p = 0.001) were signiﬁ-
cant predictors of permeability in MS NEL. The overall model ﬁt was
R2 = 0.37 and p = 0.001 with no signiﬁcant interaction between the
two parameters. In periventricular NAWMwe saw the same trend with
treatment (Beta = −0.011 mL/100 g/min, p = 0.42) and relapsewithin
the last three months (Beta = 0.041 mL/100 g/min, p = 0.004), with
signiﬁcant model ﬁt of R2 = 0.31 and p = 0.01. Relapse within the last
sixmonths (n = 17), relapse at time of investigation (n = 3), total num-
ber of relapses within one year, and presence of one or more contrast-
enhancing lesions (CELs) (5 patients) could not predict permeability in
periventricular NAWMorNEL. In a post-hoc analysis wewanted to inves-
tigate a possible effect of immunomodulatory treatment on permeability
after an MS relapse. Regression analysis showed that in MS patients
receiving treatment, a logarithmic functionbest explained the relationbe-
tween number of days since onset of last relapse and permeability in NEL
(R2 = 0.42, beta = −0.052, p = 0.004) and periventricular NAWM
(R2 = 0.30, beta = −0.028, p = 0.019) (Fig. 5). In other words, for
every 100% increase in days since onset of lastMS relapse, the permeabil-
ity decreased by 0.052 mL/100 g/min in NEL and 0.028 mL/100 g/min in
periventricular NAWM. In the no treatment group we did not ﬁnd such a
correlation. To investigatewhether theMS patients with no relapsewith-
in 3 months (n = 17) showed higher permeability than healthy controls,
we compared periventricular NAWM to the cerebral white matter of
healthy controls and still found signiﬁcantly higher permeability values
(p = 0.00011; one-sided T test). Comparing mean permeability in MS
NELs (n = 274) to the periventricular NAWM, we found no signiﬁcant
difference (paired T test). A subgroup analysis comparing isointense and
hypointense (black holes) lesions as seen on T1 weighted MRI did not
show any signiﬁcant differences in permeability (data not shown).
Fig. 2. Tissue enhancement curves, Patlak plots and derived parameters for one MS patient (left column) and one healthy control (right column). “Time” on the x-axis of the Patlak plot,
corresponds to ∫0t Ca(τ)dτ/Ca(t). Abbreviations: NAWM = normal appearing white matter. NEL = non-enhancing lesion. Vb = blood volume.
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In this study we report the novel ﬁnding of signiﬁcantly increased
permeability of the BBB in MS periventricular NAWM compared to
healthy white matter of controls. A recent study using a similar MRI
method to investigate only MS patients, reported a mean Ktrans of 0.04
(SD 0.03) mL/100 mL/min in periventricular NAWM (Ingrisch et al.,
2012). In our study we ﬁnd slightly higher values, which could be due
to methodological differences, e.g. shorter total sampling time of
7 min, usage of a two compartment model with more parameters to
ﬁt, and also differences in the study cohorts. Firstly, we did not include
secondary progressive MS patients, where the relationship between in-
ﬂammation and damage to the BBB is less obvious than in RRMS
(Lassmann et al., 2012), secondly, our cohorts were all evaluated for
treatment intensiﬁcation, thus presumably having a high relative dis-
ease activity (10 patients had one or more relapses within the lastthree months). In healthy controls, the ﬁnding of low grade leakage
seems in good agreement with the previously estimated PET value of
0.03 mL/100 g/min (SD 0.008) (Ki = 0.0003 min−1) reported by
Iannotti et al. (1987). Although previous studies using ΔR1 / Δt after
gadolinium administration to compare leakage in MS NAWM and
white matter in healthy controls have not found signiﬁcant differences,
they report a non-signiﬁcant trend for elevated signal (Silver et al.,
2001) and a higher coefﬁcient of variation (Lund et al., 2013) in
NAWM in MS patients. First of all, both studies included a relatively
low number of healthy controls (Silver, n = 5; Lund, n = 9) and sec-
ondly, all patients in the study by Lund and colleagues received immu-
nomodulatory treatment. Lastly, scanner instability due to changes in
hardware, etc. may blur results if patients and controls are scanned at
different time periods. All these factors may have contributed to not
ﬁnding a signiﬁcant difference. In MS patients we observe higher per-
meability in periventricular NAWM compared to thalamic gray matter
Fig. 3. Permeability of the blood–brain barrier showing signiﬁcantly higher values both in
MS periventricular NAWM compared to cerebral white matter of healthy controls
(p = 0.9 × 10−5; one-tailed T test), and in thalamic gray matter (p = 0.003; one-tailed
T test). Black line = median. Boxes = 25% and 75% percentiles. Whiskers = sample
range, outliers marked by circles. NB! All outliers were included in statistical analysis.
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edge of anatomical predilection areas of MS lesions which are often lo-
cated near the ventricles, less commonly occurring in the cortical NAGM
and even rarer in the thalamus. It must be noted, however, that inFig. 4. InMS patients with clinical relapse within the last threemonths (n = 10), we found sign
(p = 0.004), and non-enhancing lesions (NELs) (p = 0.003; two-tailed T tests) compared to t
signiﬁcantly lower permeability in NEL (p = 0.01; two-tailed T test). Linear regression analysi
the last three months (Beta = 0.034 mL/100 g/min, p = 0.001) were signiﬁcant predictors
signiﬁcant interaction between the two parameters. Values for healthy controls are added for c
range, outliers marked by a circle. Treatment = immunomodulatory treatment with IFN-betaNAGM we were not able to visualize and exclude gray matter MS le-
sions. Hence, some lesionsmight have been included in theNAGM, blur-
ring the picture. In visibly non-enhancing lesions we ﬁnd similar
permeability when compared to periventricular NAWM, a ﬁnding
which is supported by Ingrisch and colleagues, using DCE with a total
sampling time of 7 min (Ingrisch et al., 2012). One earlier study by
Soon and colleagues did however report a higher degree of leakage in
inactive MS lesions when compared to contralateral NAWM (Soon
et al., 2007). This leakage was primarily observed to occur 20 and
40 min post-contrast, and previous work suggests that low permeating
MS lesions may not reach maximum concentration of contrast agent
until 2 h after injection (Tofts, 1995). We have no good explanation
for these discrepancies in results, and whether ΔR1 / Δt after contrast
injection or DCE is more sensitive for measuring very subtle changes
in BBB permeability is currently not known.
4.1. Relapse activity
We found relapse within the last three months to be a signiﬁcant
predictor of permeability in periventricular NAWM, thalamus and NEL.
We are aware of two MRI studies describing a similar phenomenon
with structural abnormalities occurring consecutively in MS lesions
and in contralateral NAWM (De Stefano, 1999; Werring, 2000). In
both cases the authors suggested cross-hemisphericalWallerian degen-
eration to explain this ﬁnding. Thewidespread and ﬂuctuating nature of
relapse related permeability changes that we observe in our data might
be more suggestive of inﬂammatory processes causing this. Hence, an
MS relapse, despite being a somewhat heterogeneous clinical entity
presenting itself with focal neurological symptoms, may just be the
“tip of the iceberg” of more widespread BBB changes with demyelinat-
ing lesions occurring when BBB permeability exceeds a certain thresh-
old. In our data, permeability in NAWM or NEL was not predicted byiﬁcantly higher permeability in periventricular NAWM (p = 0.004), thalamic gray matter
hose with no relapse within three months. Immunomodulatory treatment coincided with
s showed that treatment (Beta = −0.021 mL/100 g/min, p = 0.039) and relapse within
of permeability in MS NEL. The overall model ﬁt was R2 = 0.37 and p = 0.001 with no
omparison. Black line = median. Boxes = 25% and 75% percentiles. Whiskers = sample
or glatiramer acetate. Relapse = one or more relapses within the last three months.
Fig. 5. InMS patients receiving immunomodulatory treatment, we found the number of days since onset of last relapse to be a signiﬁcant predictor of permeability in MS non-enhancing
lesions (A), and periventricular normal appearing whitematter (B). In the untreated groupwe found no such relation. Data points = mean value for each subject. Continuous line =
logarithmic ﬁt line; y = a − b∗log(x). R sq = R2. IFN-beta = interferon beta. GA = glatiramer acetate.
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(b3 mm)CEL each, and no history of recent clinical relapse activity. This
seems to ﬁt well with previous works, which have shown poor correla-
tion between CELs and clinical symptoms (Harris et al., 1991; Kermode
et al., 1990). An important limitation is of course that only ﬁve patients
had one or more CEL, thus yielding low statistical power.
4.2. Immunomodulatory treatment
Treatment coincided with signiﬁcantly lower permeability in NEL in
MS patients having had no relapse within the last three months. This
could be a direct effect of treatment that “normalizes” the BBB to a
more impermeable state during stable disease periods. In the treated
MS patients a logarithmic function best explained the relation between
permeability in MS NEL and periventricular NAWM and the number of
days since onset of last relapse. In other words, shortly after a relapse
when the permeability is high, immunomodulatory treatment may act
to speed up the rate of closing of the BBB, ending up at a level that is
comparable to healthy controls (Fig. 5). Given that the total number of
relapses within the last year could not predict permeability, it appears
that this is indeed a time effect and not just related to overall higher re-
lapse activity. At least in the case of IFN-beta-1a, it has been shown to
stabilize barrier characteristics of human brain capillary endothelial
cells in vitro (Kraus et al., 2008). This would serve to explain why
some studies ﬁnd no difference between healthy controls and MS pa-
tients undergoing immunomodulatory treatment (Lund et al., 2013)
or having no recent relapses (Silver et al., 2001). Further study of the
temporal evolution of permeability before, during and after occurrence
of anMS relapse in treated and untreatedMS patients is needed to shed
further light on this matter.
4.3. Disruption of the blood–brain barrier in MS
The idea of a disrupted BBB as a prerequisite for developingMS is not
new. According to onemajor theory, put forward by Poser in 1986, four
elements are required in order to develop MS: 1) genetic susceptibility,
2) an environmental and probably viral immune-mediated event, 3) al-
teration of the BBB function and 4)myelinoclastic plaque-forming capa-
bility in the CNS (Poser, 1986). Our results indicate that such a BBB
disruption is present in MS on a widespread level in the CNS being
more pronounced in areas prone to development of MS lesions. Even
patientswithout a relapsewithin the last 3 months showhigher perme-
ability compared to control, leading us to speculate as towhether an un-
derlying pathology of the BBB could be present in MS. However, the MS
disease process itself seems capable of modifying the permeability of
the BBB (Larochelle et al., 2011; Minagar and Alexander, 2003) but we
observed no correlation between permeability and age, EDSS or years
sinceMS onset indicating that BBB abnormalities do not seem toworsen
with disease progression. This question could be addressed further by
investigating a large cohort of treatment naive patients with clinically
isolated syndrome or early MS. The large body of evidence supporting
BBB dysfunction in MS is reviewed in detail elsewhere (Poser, 1986,
1992, 2004) with two main points. First, both MS patients and many
healthy individuals have autoreactive T cells against self-antigens such
as myelin-basic-protein (MBP) circulating in the blood (Elong Ngono
et al., 2012), arguing that a barrier defect is needed to develop the dis-
ease. Second, no single triggering event or pathogen has been found
so far that can trigger MS or cause relapses in patients with existing
MS (Owens and Bennett, 2012). On the contrary, evidence indicates
that infection with many different pathogens, either bacterial or viral,
increases the risk of relapse up to twofold, gives more severe relapses
and shows increased lesion activity on MRI (Correale et al., 2006).
Even trauma and certain chemical effects seem to be able to initiate
the plaque forming process in some MS cases (Poser, 1994). If a weak
barrier function is present in MS this could lead to higher sensitivity to
various irritants, initiating a subsequent immune response. Recentworks even suggest that Epstein–Barr virus, which has long been linked
toMS (Owens and Bennett, 2012; Pakpoor et al., 2013), is capable of in-
fecting the human endothelial cells of the BBB (Casiraghi et al., 2011).
The authors propose a model of reactivation of latent EBV, which leads
to an increased production of pro-inﬂammatorymediators and immune
cell adherence inducing a breach in the BBB. In an individual with an in-
creased level of peripheral autoreactive T cells, this could lead to an ini-
tial localized entry of immune cells and the development of CNS lesions.
Only a minority of cells need be infected and express viral genes, which
would serve to explain the inconsistent detection of EBV in MS brains
(Willis et al., 2009) and CSF (Mancuso et al., 2010). Hence, we raise
the question as to whether dysfunction or dysmaturation of the BBB
could make certain predisposed individuals more prone to later devel-
opment of MS.
5. Conclusion
Our results emphasize the importance of BBB pathology in MS,
which we ﬁnd to be most prominent in the periventricular NAWM, an
area prone to development of newMS lesions. Given that recent relapse
coincides with higher permeability in NEL, periventricular NAWM and
thalamic gray matter, and that permeability in NEL is lower in patients
undergoing immunomodulatory treatment, it appears that BBB perme-
ability depends upon the current level of generalized MS inﬂammatory
activity. Our method holds promise of being a non-invasive tool for
monitoring relapse activity and/or treatment effect. Furthermore, it
could be used to investigate whether an underlying pathology of the
BBB is present in MS if applied on a larger group of treatment naive pa-
tients with clinically isolated syndrome or early MS.
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